Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Sunshine Heart Inc Announces Conditional Approval Of IDE From FDA for C-Pulse Heart Assist System
Sunshine Heart Inc announced that it has received conditional approval from the FDA for an Investigational Device Exemption (IDE) for its flagship C-Pulse Heart Assist System.
Latest Key Developments in Advanced
- Covidien PLC Receives FDA 510(k) Clearance For Nellcor Pulse Oximetry Motion Claims
- Toumaz Ltd Announces Issue Of Equity In Relation To Deferred Consideration
- Natus Medical Inc Reaffirms Q2 2013 Guidance; Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
- Japan Asia Group Ltd Sells Shares of ImageONE Co Ltd
- Share this
- Link this
- Digg this
Follow Reuters